Drugs / PPMX-T003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05074550 | Aug 2022 → Aug 2023 | acquired polycythemia vera | Perseus Proteomics Inc. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05863234 | Sep 2023 → Mar 2026 overdue | aggressive NK-cell leukemia | Hiroshima University Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PPMX-T003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05863234 ↗ |
| Modality | Monoclonal antibody | “a fully human monoclonal antibody targeting the transferrin receptor 1” PMID 40588385 ↗ Jun 2025 |
| Route | Intravenous | “Single Intravenous PPMX-T003” NCT05074550 ↗ |